Market News How it works Learn FAQ
| RCT 0.0827 8.67% | NU 12.59 -16.95% | EWZ 34.15 -19.82% | BBD 2.93 -28.01% | TGL 0.2427 9.57% | AZTR 1.53 113.99% | ITUB 7.7 -20.37% | XP 15.705 -48.36% | NVD 3.99 -4.77% | SRTM 0.3 -30.28% | WFF 0.0898 12.25% | SPCX 146.9 -0.40% | PBR 22.5 -13.99% | SHFS 0.094 -29.00% | SOXL 90.5 8.31% | INTC 90.47 4.04% | VALE 12 -3.23% | NVDA 216 2.39% | CLRO 4.97 52.92% | NOK 8.64 6.14% | JBLU 2.37 -9.71% | TSLL 10.76 10.25% | CRWV 55.19 1.76% | GCDT 0.1545 -12.27% | SOXS 47.98 -8.54% | RIG 6.53 1.87% | NWGL 0.0869 5.98% | ABEV 2.83 -14.24% | RWM 14.5 -0.34% | BITO 10.65 -1.66% | AAL 12.2 0.74% | GPUS 0.1785 5.68% | TSLG 5.38 10.47% | T 20.85 -0.38% | SGRY 23.25 47.62% | IREN 25.43 2.11% | INTR 4.68 -34.91% | SBS 4.73 -26.09% | NFLX 63.9 -2.96% | GRAB 2.71 -2.87% | TSLA 391.62 5.21% | QID 14.22 -2.27% | WULF 11.98 5.83% | TQQQ 68.43 3.23% | CIFR 7.71 -2.90% | RBNE 0.17 -10.53% | SID 0.9118 -22.73% | SPDN 8.5 -0.47% | VZ 43.1 -3.49% | LUCD 0.5007 21.82%
ALALX Oncology Holdings Inc. logo

ALX Oncology Holdings Inc. (ALXO)

NASDAQ · Currency in USD
$1.13 ▼ -0.04 (-3.42%)
At close: Oct 26, 4:00 PM ET. Market closed.
$1.13 ▲ +0.00 (+0.00%)
After hours: Oct 26, 4:10 PM ET

Summary

Previous Close
$1.17
Open
$1.19
Day's Range
$1.09 – $1.19
52 Week Range
$0.86 – $2.66
Volume
1,037,527
Avg. Volume
1,314,551
Market Cap
$156.25M
Beta (5Y Monthly)
0.40
PE Ratio (TTM)
--
EPS (TTM)
-$0.60
Earnings Date
Nov 6, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$17.90

Profile: ALX Oncology Holdings Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
48
CEO
Jason Lettmann

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatamab, under phase 1b/2 trial for the treatment of breast cancer and other solid tumors; HER2 with an ADC, fam-trastuzumab deruxtecan-nxki, under phase 1 trial for the treatment of patients with breast cancer; ALX2004, under phase 1 clinical trial for treating solid tumors; MD Anderson Cancer Center with rituximab and lenalidomide for the treatment of patients with indolent and aggressive NHL; and Sanofi with isatuximab and dexamethasone, under phase 1/2 trial for the treatment of patients with relapsed or refractory multiple myeloma.

Earnings

Next report: Fri, Nov 6, 2026
EPS estimate -$0.15
DateEst.Actual
Aug 6, 2026-$0.14-$0.13Beat
May 8, 2026-$0.15-$0.17Miss
Feb 27, 2026-$0.38-$0.42Miss
Nov 7, 2025-$0.37-$0.41Miss
Aug 12, 2025-$0.46-$0.49Miss
May 8, 2025-$0.47-$0.58Miss

Analyst view

Consensus price target
$17.90 ▲ +1,484.1%
Range $1.50 – $38.00
Rating: Buy
Buy 86% · Hold 14% · Sell 0%

Get free alerts on ALXO and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.